Literature DB >> 17520409

Accuracy of preoperative tumor grade and intraoperative gross examination of myometrial invasion in patients with endometrial cancer.

Koen Traen1, Berit Hølund, Ole Mogensen.   

Abstract

BACKGROUND AND AIMS: Preoperative prediction of metastases to the regional lymph nodes in women with endometrioid endometrial cancer is a challenge. According to the Danish Gynaecological Cancer Society guidelines, a pelvic lymphadenectomy is warranted in all poorly differentiated tumors and all stage Ic disease. We have evaluated the accuracy of preoperative tumor grade and intraoperative gross examination of myometrial invasion, in predicting the need for a pelvic lymphadenectomy.
METHODS: Preoperative tumor grade and intraoperative gross examination of myometrial invasion were prospectively registered in 72 women with stage I endometrioid endometrial cancer, operated between 1 September 2004 and 18 April 2006. The pre- and intraoperative findings were compared with the final pathology report.
RESULTS: The preoperative prediction of grade (well, moderate or poorly differentiated) was correct in 96% (69/72) of the patients. Gross examination of myometrial invasion correctly differentiated between stage Ia, Ib, and Ic disease in 89% (64/72) of the patients. The combination of preoperative tumor grade and intraoperative gross examination of myometrial invasion, led to wrong clinical decisions in 11% (8/72) of the patients. Three 'unnecessary' lymphadenectomies were performed, and 5 patients were primary operated upon without 'warranted' lymphadenectomy.
CONCLUSIONS: Our data suggest that preoperative tumor grade and intraoperative gross examination of the uterus provide useful information for pre-and intraoperative planning of pelvic lymphadenectomy. However, wrong decisions were made in 11% of the patients, and more reliable evaluation methods are needed.

Entities:  

Mesh:

Year:  2007        PMID: 17520409     DOI: 10.1080/00016340701322077

Source DB:  PubMed          Journal:  Acta Obstet Gynecol Scand        ISSN: 0001-6349            Impact factor:   3.636


  6 in total

1.  Prediction of staging with preoperative parameters and frozen/section in patients with a preoperative diagnosis of grade 1 endometrioid tumor in endometrial cancer.

Authors:  Alper Karalok; Işın Ureyen; Yıldız Reis; Ozge Oktay; Taner Turan; Nurettin Boran; Dilek Bülbül; Gökhan Tulunay; Mehmet Faruk Köse
Journal:  J Turk Ger Gynecol Assoc       Date:  2014-01-30

2.  The Accuracy of Integrated [(18)F] Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Detection of Pelvic and Para-aortic Nodal Metastasis in Patients with High Risk Endometrial Cancer.

Authors:  Nikhil Shirish Gholkar; Subhas Chandra Saha; Grv Prasad; Anish Bhattacharya; Radhika Srinivasan; Vanita Suri
Journal:  World J Nucl Med       Date:  2014-09

3.  Are preoperative histology and MRI useful for classification of endometrial cancer risk?

Authors:  Noemie Body; Vincent Lavoué; Olivier De Kerdaniel; Fabrice Foucher; Sébastien Henno; Aurélie Cauchois; Bruno Laviolle; Marc Leblanc; Jean Levêque
Journal:  BMC Cancer       Date:  2016-07-19       Impact factor: 4.430

4.  Interactions between microRNA-200 family and Sestrin proteins in endometrial cancer cell lines and their significance to anoikis.

Authors:  Joanna Kozak; Paulina Wdowiak; Ryszard Maciejewski; Anna Torres
Journal:  Mol Cell Biochem       Date:  2019-05-09       Impact factor: 3.396

5.  Can addition of frozen section analysis to preoperative endometrial biopsy and MRI improve identification of high-risk endometrial cancer patients?

Authors:  Go Nakai; Yoshikazu Tanaka; Takashi Yamada; Masahide Ohmichi; Kazuhiro Yamamoto; Keigo Osuga
Journal:  BMC Cancer       Date:  2021-11-04       Impact factor: 4.430

6.  Assessment of endometrial sampling as a predictor of final surgical pathology in endometrial cancer.

Authors:  L Helpman; R Kupets; A Covens; R S Saad; M A Khalifa; N Ismiil; Z Ghorab; V Dubé; S Nofech-Mozes
Journal:  Br J Cancer       Date:  2013-12-24       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.